# A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT04568304** · PHASE3 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 364 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Toripalimab Injection
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Cisplatin for Injection / Carboplatin Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04568304
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-30
- **Primary completion:** 2023-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 364 (ESTIMATED)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568304, "A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04568304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*